Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage
Status:
Completed
Trial end date:
2002-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe and Oceania. The aim of this trial is to evaluate the
safety and preliminary efficacy of activated recombinant human factor VII (NovoSeven®) in
preventing early haematoma growth in acute Intracerebral Haemorrhage (ICH).